Φορτώνει......
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
PURPOSE: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the Aurora B kinase inhibitor BI 811283 in patients with advanced solid tumors. METHODS: BI 811283 was administered via 24-h infusion on Days 1 and 15 of a...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Chemother Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080318/ https://ncbi.nlm.nih.gov/pubmed/27349901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3095-6 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|